| Follow Us: Facebook Twitter

News

HistoSonics adds 3 staff as it continues clinical trial

Clinical trials and venture capital. Those are major milestones the team at HistoSonics is working to hit before the end of this year.

The Ann Arbor-based life sciences startup is aiming to finish raising a Series B round of venture capital and finish its first clinical trial by the end of this year.

"Those are our two biggies," says Christine Gibbons, president & CEO of HistoSonics.

HistoSonics spun out of the University of Michigan four years ago. It's primary product is a medical device that uses tightly focused ultrasound pulses to treat prostate disease in a non-invasive manner with robotic precision. The technology helped inspire the company's name by combining histo (meaning tissue) and sonics (meaning sound waves).

HistoSonics has a team of 11 people after adding three new researchers over the last year. It is currently working on a completing a clinical study measuring the safety of their product. The startup is aiming to submit its technology to the FDA for approval in 2016.

HistoSonics also raised $11 million in Series A funding in 2009. It is seeking another $12 million to $15 million in a Series B round this year.

"We have gotten some interim funding from our investors so we haven't had to raise a Series B yet," Gibbons says. "We want to get that wrapped up by early fall."

Source: Christine Gibbons, president & CEO of HistoSonics
Writer: Jon Zemke
Signup for Email Alerts
Signup for Email Alerts

Related Company

  • HistoSonics
    3626 W Liberty St
    Ann Arbor, MI 48103 Website
    HistoSonics is a medical device company that is developing Histotripsy, a non-invasive image guided and robotic tissue ablation technology that was licensed from the University of Michigan. Histotripsy is a versatile platform that will replace ...